GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr N Hirons |
||||
b) |
Position/status |
SVP, Global Ethics & Compliance |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
||||
b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2017-04-24 |
||||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr B McNamara |
||||
b) |
Position/status |
CEO, Consumer Healthcare |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-24 |
||||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr D E Troy |
||||
b) |
Position/status |
SVP & General Counsel |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-24 |
||||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |